Royalty Report: Drugs, Medical, Biotechnology – Collection: 2550

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Medical
  • Biotechnology
  • Cancer
  • Surgical
  • cell therapy
  • Disease
  • Pharmaceuticals
  • Supply
  • Stem cells
  • Therapeutic
  • Tissue
  • Drug Discovery
  • Wound Care
  • Test/Monitoring
  • Genome
  • Assay
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2550

License Grant
The Company hereby grants a worldwide, non-exclusive, non-transferable, non-assignable, non-sublicensable  terminable license under the Intellectual Property that is the subject of Medtronic’s infringement, to make, have made, use, import, distribute, sell, have sold the Licensed Products incorporating or utilizing such Subject Technology within the Medtronic Area of Interest.
License Property
Medtronic Area of Interest means the areas of cardiovascular (excluding the tissue-engineered vascular grafts), endocrine, neurological, and spinal conditions or diseases.

A. ISSUED U.S. PATENTS
4,721,096   Process for Replicating Bone Marrow In Vitro and Using the Same
4,960,489   Three-Dimensional Cell and Tissue Culture System
5,032,508   Three-Dimensional Cell and Tissue Culture System
5,160,490   Three-Dimensional Cell and Tissue Culture System Apparatus
5,266,480   Three-Dimensional Skin Culture System
5,443,950   Three-Dimensional Cell and Tissue Culture System
5,460,939   Temporary Living Skin Replacement
5,478,739   Three-Dimensional Stromal Cell and Tissue Culture System
5,510,254   Three-Dimensional Cell and Tissue Culture System
5,512,475   Three-Dimensional Skin Cell and Tissue Culture System
5,516,680   Three-Dimensional Kidney Cell and Tissue Culture System
5,516,681   Three-Dimensional Pancreatic Cell and Tissue Culture System
5,518,915   Three-Dimensional Mucosal Cell and Tissue Culture System
5,541,107   Three-Dimensional Bone Marrow Cell and Tissue Culture System
5,559,022   Liver Reserve Cells
5,578,485   Three-Dimensional Blood-Brain Cell and Tissue Culture System
5,580,781   Three-Dimensional Tumor Cell and Tissue Culture System
5,599,788   Method for Accelerating Skin Wound Healing with H3 Protein
5,624,840   Three-Dimensional Liver Cell and Tissue Culture System
5,714,588   Enhancement of Cellular Attachment Using H3 Protein
5,763,267   Apparatus for the Large Scale Growth and Packaging of Cell
            Suspensions and Three-Dimensional Tissue Cultures
5,785,964   Three-Dimensional Genetically Engineered Cell and Tissue Culture
            System
5,792,603   Apparatus and Method for Sterilizing, Seeding, Culturing, Storing,
            Shipping and Testing Tissue, Synthetic or Native, Vascular Grafts
5,827,729   Diffusion Gradient Bioreactor and Extracorporeal Liver Device
            Using a Three-Dimensional Liver Tissue
5,830,708   Methods for Production of a Naturally Secreted Extracellular Matrix
5,842,477   Method for Preparing Cartilage
5,843,766   Apparatus for the Growth and Packaging of Three Dimensional
            Tissue Cultures
5,846,828   Apparatus and Method for Sterilizing, Seeding, Culturing,
            Storing, Shipping and Testing Tissue, Synthetic, or Mechanical
            Heart Valves or Valve Segments
5,849,588   Methods of Use of a Three-Dimensional Liver Cell and Tissue
            Culture System
5,858,721   Three-Dimensional Cell and Tissue Culture System
5,863,531   In Vitro Preparation of Tubular Tissue Structures by Stromal Cell
            Culture on a Three-Dimensional Framework
5,902,741   Three Dimensional Cartilage Cultures
5,919,702   Production of Cartilage Tissue Using Cells Isolated From
            Wharton's Jelly

5,928,945   Application of Shear Flow Stress to Chondrocytes or Chondrocytre
            Stem Cells to Produce Cartilage
5,962,325   Three-Dimensional Stromal Tissue Cultures
6,008,049   Diffusion Gradient Bioreactor and Extra-Corporeal Liver Device
6,022,743   Three-Dimensional Culture of Pancreatic Parenchymal Cells
            Cultured Living Stromal Tissue Prepared In Vitro
6,027,935   Gene Up-Regulated in Regenerating Liver
6,060,306   Apparatus and Method for Sterilizing, Seeding, Culturing, Storing,
            Shipping and Testing Replacement Cartilage Tissue Constructs
6,121,042   Apparatus and Method for Simulating In Vivo Conditions While
            Seeding And Culturing Three-Dimensional Tissue Constructs
6,140,039   Three-Dimensional Filamentous Tissue Having Tendon or Ligament
            Function
6,218,182   Method For Culturing Three-Dimensional Tissue in Diffusion
            Gradient Bioreactor and Use Thereof
6,284,284   Compositions and Methods for Production and Use of an Injectable
            Naturally Secreted Extracellular Matrix
6,291,240   Cells or Tissues With Increased Protein Factors and Method of
            Making Same

B. PENDING U.S. PATENT APPLICATIONS
08/488,165  Three-Dimensional Human Cell Cultures on Cardiac Valve Frameworks
            and Their Uses – on appeal
08/660,787  Compositions and Methods for Production and Use of an Injectable,
            Naturally Secreted Extracellular Matrix
09/256,649  Living Chimeric Skin Replacement
09/313,538  Conditioned Cell Culture Medium Compostions and Methods of Use
09/362,948  Genetically Engineered Cells Responsive to Environmental Cues
09/350,386  Human Naturally Secreted Extracellular Matrix-Coated Device and
            Methods for the Production and Uses Thereof
09/401,445  Three Dimensional Human Cell Cultures on Cardiac Valve Frameworks
            and Their Uses
09/411,585  Methods of Using a Three-Dimensional Stromal Tissue to Promote
            Angiogenesis
09/457,519  Application of Shear Flow Stress to Smooth Muscle Cells for the
            Production of Implantable Structures
09/482,203  Apparatus and Method for Sterilizing, Seeding, Cultiring, Storing,
            Shipping and Testing Tissue Synthetic or Native Vascular Grafts
09/603,642  Monitorable Three Dimensional Scaffolds and Tissue Culture
09/724,410  Cells or Tissues with Increased Protein Factors and Methods for
            Making Same
09/847,902  Container for Shipping Tissue
60/297,177  Compositions Comprising Conditioned Cell Culture Media and Uses
            Thereof

II. UNITED STATES PATENTS LICENSED TO ADVANCED TISSUE SCIENCES, INC.

A. LICENSED FROM THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY
4,418,691   Method of Promoting the Regeneration of Tissue at a Wound
4,458,678   Cell-Seeding Procedures Involving Fibrous Lattices
4,505,266   Method of Using a Fibrous Lattice
4,638,045   Non-Peptide Polyamino Acid Bioerodible Polymers
4,806,621   Biocompatible, Bioerodible, Hydrophobic, Implantable Polyamino
            Carbonate Article
4,947,840   Biodegradable Templates for the Regeneration of Tissues
5,041,138   Neomorphogenesis of Cartilage In Vivo From Cell Culture
5,128,420   Method of Making Hydroxamic Acid Polymers From Primary Amide
            Polymers
5,399,665   Biodegradable Polymers For Cell Transplantation
5,514,378   Biocompatible Polymer Membranes and Methods of Preparation of Three
            Dimensional Membrane Structures
5,516,532   Injectable Non-Immunogenic Cartilage and Bone Preparation
5,654,381   Functionalized Polyester Graft Copolymers
5,736,372   Biodegradable Synthetic Polymeric Fibrous Matrix Containing
            Chondrocyte For In Vivo Production of a Cartilaginous Structure
5,759,830   Three-Dimensional Fibrous Scaffold Containing Attached Cells for
            Producing Vascularized Tissue In Vivo
5,770,193   Preparation of Three-Dimensional Fibrous Scaffold For Attaching
            Cells to Produce Vascularized Tissue In Vivo
5,770,417   Three-Dimensional Fibrous Scaffold Containing Attached Cells for
            Producing vascularized Tissue In Vivo
5,804,178   Implantation of Cell-Matrix Structure Adjacent Mesentery, Omentum or
            Peritoneum Tissue
6,123,727   Tissue Engineered Tendons and Ligaments
6,095,148   Neuronal Stimulation Using Electrically Conducting Polymers
6,224,893   Semi-Interpenetrating or Interpenetrating Polymer Network for Drug
            Delivery and Tissue Engineering

B. LICENSED FROM THE UNIVERSITY OF FLORIDA
5,650,299   Cells Producing Stem Cell Proliferation Factor
5,981,708   Stem Cell Proliferation Factor

IPSCIO Record ID: 266751

License Grant
Licensor, non-profit health care organization, grants the worldwide right and exclusive license, with the right to grant sublicenses, under the Patent Rights to make, have made, use, lease, sell, offer for sale and import for use or resale the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field.

Licensor also grants a non-exclusive license to Know-how, and a non-exclusive license to use Biological Materials in connection with licensees research and development of Licensed Products.

License Property
The patents include Reconstruction of Urological Structures with Polymeric Matrices;  Achievement of Excretory Renal Function Using a Neo-Morphogenic System In Vivo; Penile Reconstruction; Ex vivo Engineered Stents for Urethral Structures; Creation of Tissue Engineered Female Productive Organs (Vagina); Augmentation of Organ Function;  and, Tissue Engineered Uterus and Fallopian Tubes.

Biological Materials shall mean the specific proprietary biological materials, including Progeny and Unmodified Derivatives of those materials.  Progeny shall mean an unmodified descendant from the material, such as a virus from virus, cell from a cell, or organism from an organism; Unmodified Derivatives shall mean substances created by the Licensee which constitute an unmodified functional subunit or product expressed by the original material, such as subclones of unmodified cell lines, purified or fractionated subsets of the original material, proteins expressed by DNA/RNA, or monoclonal antibodies secreted by a hybridoma cell line; and Modifications shall mean substances created by the Licensee which contain or incorporate the material.

Field of Use
Field of Use shall mean the development and commercialization of tissue engineered products for human and animal therapeutics in the subfields of genitourinary, vascular tissue, nervous tissue, trachea and other subfields when and if mutually agreed upon by the parties in writing.

IPSCIO Record ID: 457

License Grant
LICENSOR, an agency of the U.S. federal government responsible for the civilian space program, as well as aeronautics and space research, hereby grants to LICENSEE a terminable, royalty-bearing, exclusive license to practice, i.e., to make, have made, use, offer to sell, sell, transfer, or dispose of, the LICENSED INVENTION as limited to the LICENSED AREA and as limited to a LICENSED FIELD OR EMBODIMENT(S).

Agreement grants a terminable, royalty-bearing, exclusive license to practice, i.e., to make, have made, use, offer to sell, sell, transfer, or dispose of relative to technology for Three-Dimensional Co-Culture Process including culture process for mammalian cells and propagation of in Vitro Human Tissue.

License Property
The process of the present invention relates to a 3-dimensional coculture process. By the process of the present invention a variety of cells may be co-cultured to produce tissue which has 3-dimensionality and has some of the characteristics of in vivo tissue. The process provides enhanced 3-dimensional tissue which creates a multicellular organoid differentiation model.

Three-Dimensional Co-Culture Process U.S. Pat No. 5,153,132 – The process of the present invention relates to a three dimensional co-culture process.  Wherein two distinct types of mammalian cells are co-cultured in a rotating bioreactor which is completely filled with culture media and cell attachment substrates.  As the size of the tissue assemblies formed on the attachment substrates changes the rotation of the bioreactor is adjusted accordingly.

Method for Culturing Mammalian Cells  U.S. Pat No. 5,153,133 – A bio-reactor system where cell growth microcarrier beads are suspended in a zero head space fluid medium by rotation about a horizontal axis and where the fluid is continuously oxygenated from a tubular membrane which rotates on a shaft together with rotation of the culture vessel.  The oxygen is continuously throughput through the membrane and disbursed into the fluid medium along the length of the membrane.

Three-Dimensional Cell to Tissue   U.S. Pat No. 5,155,034 – The present invention relates to a 3-dimensional cell to tissue and maintenance process, more particularly to methods of culturing cells in a culture environment, either in space or in a gravity field, with minimum fluid shear stress, freedom for 3-dimensional spatial orientation of the suspended particles and localization of particles with differing or similar sedimentation properties in a similar spatial region.

Method for Culturing Mammalian Cells  U.S. Pat No. 5,155,035 – A bio-reactor system wherein a tubular housing contains an internal circularly disposed set of blade members and a central tubular filter all mounted for rotation about a common horizontal axis and each having independent rotational support and rotational drive mechanisms. The housing, blade members and filter preferably are driven at a constant slow speed for placing a fluid culture medium with discrete microbeads and cell cultures in a discrete spatial suspension in the housing. Replacement fluid medium is symmetrically input and fluid medium is symmetrically output from the housing where the input and the output are part of a loop providing a constant or intermittent flow of fluid medium in a closed loop.

Multi-Cellular Three-Dimensional   U.S. Pat No. 5,308,764 – The present invention relates to a multicellular, three-dimensional, living mammalian tissue. The tissue is produced by a co-culture process wherein two distinct types of mammalian cells are co-cultured in a rotating bioreactor which is completely filled with culture media and cell attachment substrates. As the size of the tissue assemblies formed on the attachment substrates changes, the rotation of the bioreactor is adjusted accordingly.

Field of Use
Licensed Field or Embodiment(s) shall mean making, using, selling, proliferating, transferring and/or making other disposition of bone marrow cells and tissues, and bone-marrow derived peripheral blood cells and applications thereof, including but not limited to growth and commercialization of bone marrow blood cell cultures, growth and transplantation of blood cells and bone marrow; and the use of blood cells and bone marrow for commercial growth of bone marrow-derived biological products, including but not limited to red blood cells, white blood cells, platelets, cellular growth factors, and intercellular communication factors, and processes for making such products. The sources of testing and commercialization materials shall be derived from sources such as living donor biopsies, harvested from cadaver donors, or from peripheral blood cells. Specifically excluded as a source of bone marrow are human embryonic, fetal or neonatal cells and tissues.

IPSCIO Record ID: 369277

License Grant
Licensor, an university division of public health sciences, hereby grants to Licensee and Licensee accepts from Licensor, an exclusive, worldwide right and license, including the right to sublicense, to make, use and sell the Improvement Products under Licensors rights in the Improvement Patents in the Licensed Field only.

Licensor hereby grants to Licensee and Licensee accepts from Licensor, a non-exclusive, worldwide, right and license, including the right to sublicense, to the Know-How.

Licensor hereby grants to Licensee and Licensee accepts from Licensor for the Option Period (in each case) a non-transferable (except as specifically stated in Agreement), exclusive option to negotiate in good faith for a royalty-bearing, worldwide, exclusive license, including the right to sublicense, to practice all the rights under the New Development Patents in the Licensed Field only (the Option).

License Property
Patent Rights
6,673,339 – Prosthetic kidney and its use for treating kidney disease
6,576,019 – Bladder reconstruction
6,514,292 – Corporal tissue penile reconstruction
Field of Use
The agreement is in the field of regenerative medicine that will advance the development of organs and tissues to treat human diseases and disabilities.

The primary focus of the research will be on creating “neo-organs” and tissues. Neo-organs and tissues are derived from a patient’s own cells that are grown on a scaffold or model that is bioresorbable, or can be absorbed by the body. These neo-organs become functional replacements after being implanted in the patient’s body. Since they come from a patient’s own cells (autologous cells) there is virtually no risk of rejection from the body’s immune system.
In tissue engineering, neo-organ is a final structure of procedure based on transplantation of constructs consisting of endogenous stem/progenitor cells grown ex vivo within predesigned matrix scaffolds. The scaffold eventually is resorbed, leaving transplanted cells and the stroma that they produce in the body.

Licensed Field means human and animal organs, tissues and tissue-engineered and regenerative medicine products directed to their functions in the following areas (i) Genitourinary Tissue, (ii) Kidney Tissue, (iii) Cardiovascular Tissue, (iv) Nervous Tissue, and (v) Trachea Tissue. Each of Genitourinary Tissue, Kidney Tissue, Cardiovascular Tissue and Nervous Tissue is a Subfield.

Genitourinary Tissue means the reproductive system and the urinary system, including the male and female internal and external genitalia as well as all organs concerned in the formation and voidance of urine, but excluding Kidney Tissue. For the removal of doubt, Genitourinary Tissue is not to be considered Cardiovascular Tissue merely because it contains components of Cardiovascular Tissue.

Kidney Tissue means the kidney.

Cardiovascular Tissue means arteries, arterial tissue, veins and venous tissue. Cardiovascular Tissue does not include cardiac muscle tissue or heart valves.

Nervous Tissue means the (i) central nervous system, (ii) peripheral nervous system, and (iii) functional subcomponents and subunits of (i) and (ii) above. For the removal of doubt, a tissue or organ is not considered Nervous Tissue merely because it contains components of Nervous Tissue.

Trachea Tissue means the trachea and functional subcomponents and subunits thereof. Trachea Tissue does not include the bronchus and larynx.

IPSCIO Record ID: 3624

License Grant
The Israeli Licensor hereby grants to the Licensee, an exclusive license to exploit in any manner and for any and all purposes the Patent, including the right to grant sublicenses, make, have made, use, market and sell the Products.
License Property
The Company entered into a License Agreement to acquire a License of stem cell expansion technology related to bone marrow transplants. The Company received an exclusive, worldwide License to use the technology over the life of the related patent. The License grants exclusivity over all products, uses and related intellectual property, and grants the Company the right to enter into sub-Licenses. This technology, if fully developed, will offer novel solutions to make procedures like bone marrow transplants and other methods of cell therapy more accessible to patients suffering from leukemia, lymphoma, myeloma and a broad range of complicated diseases and disorders.

IPSCIO Record ID: 305481

License Grant
Licensor grants a sole and exclusive worldwide license or sublicense, as applicable, to the Licensor Technology for the CPS in the Field.
License Property
The patents include  Apparatus and Method for Maintaining  and Growing Biological Cells;  Methods of Increasing Rates of !n!ection by Directing Motion of Vectors;  Methods, Compositions and Apparatus for Cell Transfection; and, Methods, Compositions and Devices for Maintaining and Growing Human Stem and/or Hematopoietic Cells.

CPS means any system or device for substantially increasing, the number of cells, ex vivo, for human therapeutic uses, that may be configured in different component structures (such as described for the Automated CPS or the Manual CPS).

Licensed Product means the Automated CPS (both the Durables and the Disposables) as used for one or more specific Lymphoid Cell Applications.

Licensor is developing proprietary process technologies and devices for a range of cell therapy applications, including stem cell therapies and gene therapy. The lead product under development, the Licensors Cell Production System (the CPS) consists of a clinical cell culture system with disposable cassettes and reagents for use in the rapidly growing stem cell therapy market.

Field of Use
Field means Lymphoid Cell Applications.  Application means (a) the expansion of any Lymphoid Cell for one or more therapeutic uses, or (b) the transfection of a specific Lymphoid Cell type modified with a naturally occurring gene or a synthetic modification thereof for a specific therapeutic use. One Application is tumor infiltrating lymphocytes (TIL), such that TIL therapy for renal cell carcinoma and TIL therapy for breast cancer are part of the same Application.

Licensee, a competitor, along with others, are in advanced stages of development of technologies and products for use in stem cell therapy and other market applications currently being pursued by the Licensor.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 26667

License Grant
We acquired the Exclusive worldwide rights to US Patent # 6129911, for Liver Stem Cells from Licensor, a non-profit  hospital.  The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.
License Property
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.  (The Company has an exclusive, long-term license agreement for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs)  US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;  US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;  US Patent #5,043,260, Perfusion Device for Hepatocytes, expires August 27, 2008;  US Patent #4,795,459, Implantable Prosthetic Device (Endothelial), expires January 3, 2006;  US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017;  US Patent #6,858,146, Artificial Liver Apparatus and Method (Sybiol), expires on February 20, 2019; and  US Patent #6,872,389, Liver Stem Cell, expires on July 8, 2019.)

IPSCIO Record ID: 391188

License Grant
The parties terminated the License, Supply and Operating Agreements and  eliminated Licensee’s membership interest in Licensor, and returned all in-process research and development assets to Licensee (the Development Assets). The agreement also provided indemnifications and complete releases by and among the parties.
License Property
Development Assets, limited to orthopedic product candidates developed using our biologics technology platform, including HST-003 and HST-004.

U.S. patents related to HST-003, HST-004, issued in the United States (U.S. Patent Nos. 8,530,415 and 9,512,403), which are also directed to the production of a tissue patch for the repair and regeneration of cells and methods of use using of extracellular matrix compositions and more specifically to proteins obtained by culturing cells under hypoxic conditions on microcarrier beads or a three-dimensional a surface in a suitable growth medium.

8,530,415 – Repair and/or regeneration of cells with a composition produced by culturing fibroblast cells under hypoxic conditions
9,512,403 – Conditioned medium and extracellular matrix compositions from cells cultured under hypoxic conditions for methods of treating tissue injury

HST-003 – for regenerating hyaline cartilage for the treatment of articular cartilage defects, consists of the following
• Physicians, and their patients, are seeking treatments that reverse cartilage degeneration.
• Less invasive procedures are preferred to preserve patient function and reduce surgical complications.
• Patients seek treatment options with shorter recovery periods and lasting treatment mechanisms that can promote more durable articular cartilage healing.
• Current treatment options fall into four key therapeutics categories, opioid, analgesic, cell/stem cell or disease modifying.
• Cartilage repair products currently on the market or in active clinical development include Collegium’s COL003, Adhera’s IT-102, Cytori’s adipose derived stem cells, Stempeucetics’ Stempeucel, Samumed’s SM-04690 and Medivir AB’s MIV-711.

HST-004 – for spinal disc repair treatment consists of the following
• Physicians, and their patients, are seeking treatments that reverse spinal disc degeneration after injury.
• Less invasive procedures are preferred to preserve patient function and reduce surgical complications that are common with such surgeries as spinal disc fusions.
• Patients seek treatment options when surgical procedures with fixation devices may not be clinically appropriate or earlier in the disease progression.  
• Current treatment options fall into four key therapeutics categories, opioid, analgesic, cell/stem cell or disease modifying.
• Spinal disc repair products currently in active clinical development include  autologous stem cell therapy (StemSpine, Novocart Disc, FibroGenesis), allogeneic cell therapy (Discogenics, Mallinkrodt) and a Wnt pathway inhibitor targeting CLK2/DYRK1A (Biosplice Therapeutics, formerly Samumed).

Field of Use
Field of use is for the treatment of articular cartilage defects and for spinal disc repair.

IPSCIO Record ID: 28927

License Grant
This exclusive, worldwide license, with the right to grant sublicenses, to make, use and sell products incorporating the Cytomatrix(TM) structure covered by U.S. Patent 5,282,861, for the purpose of culturing, maintaining and expanding human and animal cells in all but dental, orthopedic and other excluded applications.
License Property
This agreement is for the rights to US and world patents for Licensee's core matrix, the Cytomatrix(TM), for the licensed rights to the matrix material for cell growth applications excluding orthopedic, musculoskeletal and dental uses.

Cytomatrix(TM) is a patented three-dimensional biomatrix product which has been exclusively licensed to us for cell culture applications.

Field of Use
Cytomatrix(TM) biomatrix is the foundation for our TranStem(TM) technology for the ex vivo growth, manipulation and storage of adult hematopoietic stem cells which live in the bone marrow ('HSCs') for transplantation back into the patient.

IPSCIO Record ID: 2705

License Grant
The University hereby grants to Licensee an exclusive world-wide license, without the right to grant sublicenses,  under Licensed Patents and to use Know-How to make, use, and sell Product(s), except that University hereby retains the right to use Licensed Patents and Know-How solely for research purposes, and except that to the extent funding from federal agencies results in Licensed Technology or Licensed Patents in addition to Project funding, the federal government may have its standard license rights with respect to such Licensed Technology or Licensed Patents.
License Property
'Licensed Technology' means all patentable inventions and Know-how for the production of red blood cells, white blood cells, platelets and bone marrow cells, which are either described in University Project proposal, or conceived or reduced to practice as part of Project, or conceived or reduced to practice, whether or not pursuant to or as part of the Project.

'Product(s)' means any red blood cells, white blood cells, platelets and bone marrow cells as well as any components, by-products, progeny or derivatives thereof and any factor, composition, substance, equipment, mechanism, device or other property and combinations thereof, the manufacture, use or sale of which would, but for this License, comprise an infringement of one or more Valid Claims.

Field of Use
A.  U.S. APPLICATION, SER. #07/366,639, OSMMN REF. #2363-022-55

        Methods, Compositions and Devices for Growing Cells.

        Filed  6/15/89

    B.  U.S. APPLICATION, SER. #07/628,343, OSMMN REF. #2363-023-55 CIP

        Methods and Compositions for the Ex Vivo Replication of Stem Cells

        and for the Optimization of Hematopoietic Progenitor Cell Cultures.

        Filed  12/17/90

    E.  U.S. APPLICATION, SER. #07/737,024, OSMMN REF. #2363-034-55

        Methods and Compositions for the Ex Vivo Replication of Stem Cells,

        for the Optimization of Hematopoietic Progenitor Cell Cultures,

        and for Increasing the Metabolism, GM-CSF Secretion and/or IL-6

        Secretion of Human Stromal Cells.

        Filed 7/29/91

    F.  U.S. APPLICATION, SER. #07/740,590, OSMN REF. #2363-035-55

        Methods for Human Gene Therapy, Including Methods and Compositions

        for the Ex Vivo Replication and Stable Genetic Transformation of Human

        Stem Cells, for the Optimization of Human Hematopoietic Progenitor Cell

        Cultures and Stable Genetic and/or IL-6 Secretion of Human Stromal

        Cells.

        Filed 8/5/91

    H.  U.S. APPLICATION, SER. #07,815,513, OSMMN REF. #2363-036-55

        Methods for Regulating the Specific Lineages of Cells Produced in

        a Human Hematopoietic Cell Culture, Methods for Assaying the Effect

        of Substances on Lineage-Specific Cell Production, and Cell Compositions

        Produced by these Cultures.

        Filed  1/2/92

    I.  U.S. APPLICATION, SER. #07/822,136, OSMMN REF. #2363-055-55

        Targeted Virus.

        Filed  1/17/92

    J.  PENDING U.S. APPLICATION, OSMMN REF. #2363-043-55

        Methods, Compositions and Devices for Maintaining and Growing Human

        Stem and/or Hematopoietic Cells.

        Filed  3/4/92

IPSCIO Record ID: 7016

License Grant
The Licensor, a non-profit health care organization, and the Licensee have entered into that certain Exclusive License Agreement with an effective date of July 2, 2007 and identified as Agreement number CMCC-6748 and wish to amend certain areas.
License Property
Patent Rights
The following patents and patent applications based on CMCC case 1455 (M.I.T. Case
Number 12084) and CMCC case 1456 (M.I.T. Case 13490Q)      
Country    Serial Number    Filing Date    Status    Issue Date
U.S.
    60/794,986    4/25/2006    Expired    00/00/00
U.S.
    11/789,538    4/25/2007    Pend    00/00/00
U.S.
    12/186,346    8/5/2008    Pend    00/00/00
PCT
    PCT/US08/72226    8/5/2008    Expired    00/00/00
Australia
    2008360388    8/5/2008    Pend    00/00/00
Brazil
    TBA-BR    8/5/2008    Pend    00/00/00
Canada
    TBA-CA    8/5/2008    Pend    00/00/00
China
    TBA-CN    8/5/2008    Pend    00/00/00
India
    TBA-IN    8/5/2008    Pend    00/00/00
Japan
    TBA-JP    8/5/2008    Pend    00/00/00
Singapore
    TBA-SG    8/5/2008    Pend    00/00/00
South Korea
    10-2011-7005148    8/5/2008    Pend    00/00/00
EPO
    EP-TBA    8/5/2008    Pend    00/00/00
PCT
    PCT/US07/067403    4/25/2007    Expired    00/00/00
Australia
    TBA- AU    4/25/2007    Pend    00/00/00
Brazil
    PI 0709638-0    10/23/2008    Pend    00/00/00
Canada
    2650804    4/25/2007    Pend    00/00/00
China
    200780022752.6    4/25/2007    Pend    00/00/00
India
    TBA    10/24/2008    Pend    00/00/00
Japan
    0    10/23/2008    Pend    00/00/00
Singapore
    200807854-5    4/25/2007    Pend    00/00/00
South Korea
    10-2008-7028672    11/24/2008    Pend    00/00/00
EPO
    7761270.3    4/25/2007    Pend    00/00/00
Hong Kong
    9106081.8    4/25/2007    Pend    00/00/00

Appendix 1B Additional Patent Rights  

I. United States Patents and Applications  

CMCC Case No. 23 (M.I.T. Case No. 4973)

United States of America Patent No. 5804178, Issued September 8,1998

“IMPLANTATION OF CELL-MATRIX STRUCTURE ADJACENT MESENTERY, OMENTUM OR PERITONEUM TISSUE”

by Linda G. Griffith, Lynt Johnson, Robert S. Langer and Joseph P. Vacanti

CMCC Case No. 25 (M.I.T. Case No. 5573)

United States of America Patent No. 5514378, Issued May 7, 1996

“BIOCOMPATIBLE POLYMER MEMBRANES AND METHODS OF PREPARATION OF THREE DIMENSIONAL MEMBRANE STRUCTURES”

by Linda G. Griffith, Robert S. Langer, Antonios G. Mikos, Georgios Sarakinos and Joseph P. Vacanti

CMCC Case Nos. 20 and 30 (M.I.T. Case No. 4279)

United States of America Patent No. 5759830, Issued June 2, 1998

United States of America Patent No. 5770417, Issued June 23,1998

“THREE-DIMENSIONAL FIBROUS SCAFFOLD CONTAINING

ATTACHED CELLS FOR PRODUCING VASCULARIZED TISSUE IN VIVO”

by Robert S. Langer and Joseph P. Vacanti

United States of America Patent No. 5770193, Issued June 23, 1998 “PREPARATION OF THREE-DIMENSIONAL FIBROUS SCAFFOLD CONTAINING ATTACHED CELLS FOR PRODUCING VASCULARIZED TISSUE IN VIVO”
by Robert S. Langer and Joseph P. Vacanti
CMCC Case No. 26 (M.I.T. Case No. 5729)
United States of America Patent No. 6309635, Issued October 30, 2011
“PREVASCULARIZED POLYMERIC IMPLANTS FOR ORGAN TRANSPLANTATION”
by James C. Gilbert, Donald E. Ingber, Robert S. Langer, James E. Stein and Joseph P. Vacanti
CMCC Case No. 389 (M.I.T. Case No. 6560)
United States of America Patent No. 7462471, Issued December 9, 2008
“POROUS BIODEGRADABLE POLYMERIC MATERIALS FOR CELL TRANSPLANTATION”
by Linda G. Griffith, Robert S. Langer, Antonios G. Mikos, Georgios Sarakinos and Joseph P. Vacanti
CMCC Case No. 415 (M.I.T. Case No. 6798)
United States of America Patent No. 6281015, Issued August 28, 2001
“LOCALIZED DELIVERY OF FACTORS ENHANCING SURVIVAL OF TRANSPLANTED CELLS”
by Robert S. Langer, David J. Mooney and Joseph P. Vacanti
CMCC Case No. 505 (M.I.T. Case No. 7138)
United States of America Patent No. 6095148, Issued August 1, 2000
“NEURONAL STIMULATION USING ELECTRICALLY CONDUCTING POLYMERS”
by Robert S. Langer, Christine E. Schmidt, Venkatiam P. Shastri and Joseph P. Vacanti
M.I.T. Case No. 6984
United States of America Patent No. 5654381, Issued August 5, 1997
“FUNCTIONALIZED POLYESTER GRAFT COPOLYMERS”
by Jeffrey S. Hrkach, Robert S. Langer and Noah Lotan
M.I.T. Case No. 13525 (CMCC Case No. 26)
United States of America Patent No. 6689608, Issued February 10, 2004
United States of America Serial No. 12/218448, Filed July 15, 2008
“POROUS BIODEGRADABLE POLYMERIC MATERIALS FOR CELL TRANSPLANTATION”
by Linda G. Griffith, Robert S. Langer, Antonios G. Mikos, Georgios Sarakinos and Joseph P. Vacanti
II. International (non-U.S.) Patents and Applications
CMCC Case No. 26 (M.I.T. Case No. 5729)
European Patent Convention Patent No. 0610423, Issued May 7, 1997
Japan Patent No. 3524919, Issued February 20, 2004
Austria Patent No. 0610423, Issued May 7, 1997
Belgium Patent No. 0610423, Issued May 7, 1997
France Patent No. 0610423, Issued May 7, 1997
Germany Patent No. 69219613, Issued May 7, 1997
Italy Patent No. 0610423, Issued May 7, 1997
Luxembourg Patent No. 0610423, Issued May 7,1997
Netherlands Patent No. 0610423, Issued May 7, 1997
Sweden Patent No. 0610423, Issued May 7, 1997
United Kingdom Patent No. 0610423, Issued May 7, 1997
“PREVASCULARIZED POLYMERIC IMPLANTS FOR ORGAN TRANSPLANTATION”
by James C. Gilbert, Donald E. Ingber, Robert S. Langer, James E. Stein and Joseph P. Vacanti
CMCC Case No. 30 (M.I.T. Case No. 4279)
Canada Patent No. 1340581, Issued June 8, 1999
“CHIMERIC NEOMORPHOGENESIS OF ORGANS BY CONTROLLED CELLULAR IMPLANTATION USING ARTIFICIAL MATRICES”
by Robert S. Langer and Joseph P. Vacanti
CMCC Case No. 415 (M.I.T. Case No. 6798)
European Patent Convention Patent No. 0794790, Issued April 17, 2002
Japan Patent No. 4361134, Issued August 21, 2009
Canada Patent No. 2207286, Issued October 7, 2003
Ireland Patent No. 0794790, Issued April 17, 2002
Belgium Patent No. 0794790, Issued April 17, 2002
Switzerland Patent No. 0794790, Issued April 17, 2002
Germany Patent No. 0794790, Issued April 17, 2002
Denmark Patent No. 0794790, Issued April 17, 2002
Spain Patent No. 0794790, Issued April 17, 2002
France Patent No. 0794790, Issued April 17, 2002
Austria Patent No. 0794790, Issued April 17, 2002
Greece Patent No. 3039884, Issued April 17, 2002
Sweden Patent No. 0794790, Issued April 17, 2002
Italy Patent No. 0794790, Issued April 17, 2002
Luxembourg Patent No. 0794790, Issued April 17, 2002
Monaco Patent No. 0794790, Issued April 17, 2002
Netherlands Patent No. 0794790, Issued April 17, 2002
Portugal Patent No. 0794790, Issued April 17, 2002
United Kingdom Patent No. 0794790, Issued April 17, 2002
“LOCALIZED DELIVERY OF FACTORS ENHANCING SURVIVAL OF TRANSPLANTED CELLS”
by Robert S. Langer, David J. Mooney and Joseph P. Vacanti
CMCC Case No. 505 (M.I.T. Case No. 7138)
New Zealand Patent No. 321886, Issued June 8, 2000
Japan Patent No. 4451929, Issued February 5,2010
South Korea Serial No. 98-703320, Filed October 31, 1996 Australia Patent No. 720275, Issued September 11, 2000
Canada Serial No. 2236749, Filed October 31, 1996
Japan Serial No. 2008-287194, Filed October 31, 1996
Japan Serial No. 2009-244981, Filed October 31, 1996
“NEURONAL STIMULATION USING ELECTRICALLY CONDUCTING POLYMERS”
by Robert S. Langer, Christine E. Schmidt, Venkatram P. Shastri and Joseph P. Vacanti

Field of Use
Field of Use shall mean the following three subfields i) treatment of nerve injury of the central nervous system including the brain, and spinal cord; ii) treatment of nerve injury of the retina and the cranial nerves; and iii) treatment of the following pathologic conditions nerve root impingement from musculoskeletal elements, demyelinated tissue, damage to neural elements exiting the spinal cord and lumbosacral region of spinal cord by administering a Licensed Product to the peripheral nerves in the intraspinal location, foraminal and extraspinal areas, extrapyramidal regions, areas of peripheral bony impingement, and for repair or treatment of neural elements following damage from prostate surgery; excluding the development and commercialization of tissue engineered products for human and animal therapeutics in the field of genitourinary.

IPSCIO Record ID: 273421

License Grant
The Parties reached a mutual understanding that the License Agreement drafted in 2001 no longer accurately reflected the business model of the Licensee, and that it contained certain restrictions and milestones that were not optimal for the commercialization of the Invention portfolio.

With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.

License Property
This license is for certain inventions, generally characterized as Adipose-Derived Stem Cells and Lattices.

The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.

Product means Research Product and Clinical Product.

Field of Use
The Field means any and all products and/or services for the research, diagnosis, and/or therapy of disease and/or disorders in humans and for cosmetic applications in humans.

Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.

The patented Celution® family of products process patients’ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation.  Licensee commercialization model is based on the sale of Celution® Systems and on generating recurring revenues from the single-use consumable sets.

Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytori’s core product, the Celution® System, provides physicians with clinical grade stem and regenerative cells.

IPSCIO Record ID: 372627

License Grant
By the 2003 agreement, Licensor granted an exclusive worldwide sublicense for the Licensed Technology in the Field of Use and the Field of Extended Use.  This amended and restated agreement is to continue the Exclusive Sublicense with the amendments.

Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.

For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.

License Property
Licensed Products means any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins and in combination with a synthetic or natural matrix, or any part thereof i.e., any product consisting essentially of rhPDGF-BB in the absence of other growth-promoting proteins without a matrix, or a synthetic or natural matrix alone, that is covered by the Licensed Patents; is developed through the use of a process that is covered by the Licensed Patents or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Patents.

Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.

Field of Use
GEM 21S was approved by the U.S. Food and Drug Administration the treatment of periodontal bone defects and gum tissue recession associated with periodontal disease.

GEM 21S® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.

GEM 21S® growth-factor enhanced matrix combines a bioactive protein – highly purified rhPDGF-BB – with an osteoconductive matrix, ß-TCP.

GEM 21S® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.

This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.

The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranio• maxillofacial osseous defects.

The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 203392

License Grant
The University grants to Licensee a world-wide license under the Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.

The University also grants to Licensee the right to issue sublicenses to third parties to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method, as long as Licensee has current exclusive rights thereto under this Agreement, except that the sublicensee may not be granted the right to further sublicense the technology.

License Property
The technology and patents are for certain inventions, generally characterized as Connective Tissue Stem Cells.  The Cell Replacement Therapy means the use of adipose-derived stem cells for the therapeutic replacement of cells and tissues damaged by disease or injury.
Field of Use
The Field of Use means Cell Replacement Therapy in humans; Gene Therapy in humans; Cosmetic Surgery and Reconstructive Surgery in humans; Research and Collaboration Services; and the development and commercialization of Consumables.

IPSCIO Record ID: 265251

License Grant
Licensor has granted to Licensee a sublicense of certain patents licensed to Licensor by the University of Utah Research Foundation (the “Utah Sublicense”), and has granted to Licensee a direct license of certain patents held by Licensor.  This License will not permit sublicensing and will be non-exclusive for medical products, devices, and services related to human tendon, and will be exclusive for all other licensed fields linked to the HyStem® Technology.

We may only develop, sell, and otherwise commercialize a product under the Utah Sublicense and HyStem License if we spend at least a low seven figure amount on research with respect to the product. Licensor will agree to provide us with a reasonable amount of the hydrogel product for the purpose of our research for we will pay Licensor’s cost of manufacturing and supplying the hydrogel.

License Property
The agreement is related to HyStem® hydrogel technology for use outside of the Licensor Exclusive Field for products that include cells. The intellectual property is connected to PSC-derived clonal embryonic progenitor cell lines (PureStem® technology) and HyStem® delivery matrices.  HyStem® is a patented biomaterial that mimics the extracellular matrix that is the structural network of macromolecules surrounding cells in the body. The extracellular matrix is essential for normal cellular function and survival of transplanted cells. Many tissue engineering and regenerative cell-based therapies are expected to benefit from the delivery of therapeutic cells in a matrix for precise localized delivery and survival. HyStem is a unique hydrogel that has been shown to support cellular attachment in vivo. Current research at medical institutions has shown that HyStem is compatible with a wide variety of cells and tissue types including those of the brain, bone, skin, cartilage, vascular system and heart. The technology underlying HyStem hydrogels was developed at the University of Utah and was been exclusively licensed to Licensor for human therapeutic applications and sublicensed to Licensee for certain fields. The HyStem technology is based on a unique thiol cross-linking chemistry to prepare hyaluronan-based matrices as hydrogels. Since the first published report in 2002, there have been numerous academic scientific publications supporting the biocompatibility of thiol cross-linked hyaluronan-based matrices and their applications as medical devices and in cell culture, tissue engineering, and animal models of cell-based therapies.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 274909

License Grant
Licensor grants to the Licensee of the United Kingdom, and its Affiliates, an exclusive license under Licensor Background Patent Rights, Licensor Future Patent Rights, Licensor Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights, and Licensor Know-How to develop, have developed, make, have made, use, sell, have sold, and import Cellular Assay Products throughout the Territory in the Cellular Assay Products Field.

Licensor grants
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights and Licensor Know-How to develop, make, use, sell, have sold, and import products throughout the relevant territories in the Limited Field and,
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights and Licensor’s interest in Joint Alliance IP Rights to develop, have developed, make, have made, use, sell, have sold, and import products throughout the relevant territories in the Limited Field.

Licensor grants an option to negotiate in good faith and on commercially reasonable terms
—  an exclusive, payable license, with the right to sublicense for the Limited Field under Licensor Alliance IP Rights, and Licensor’s interest in Joint Alliance IP Rights, and;
—  a sub-license for the Cellular Assay Products Field in the Territory.

License Property
The patents and know-how are for certain intellectual property rights related to the propagation and differentiation of human embryonic derived cells.
Field of Use
The Cellular Assay Products Field shall mean the use of Cellular Assay Products for in vitro assay applications, including but not limited to drug discovery and development, drug monitoring, drug toxicology testing, and consumer products testing, but excluding the use of any Cellular Assay Product in any therapeutic or diagnostic application.

The Licensor Field shall mean therapies that comprise, or are derived from, or developed or manufactured using, human embryonic stem cells.

The Limited Field shall mean products or services that contain cells that comprise, or are derived from, or manufactured using, human embryonic stem cells (and not human induced pluripotent stem cells) in markets outside of the Licensor Field and the Cellular Assay Products Field.

Cellular assay products derived from human embryonic stem cells (hESCs) is for use in drug discovery, development and toxicity screening.

IPSCIO Record ID: 26263

License Grant
Licensor hereby grants to Licensee, a royalty bearing, exclusive, worldwide License in the Field of  research, development, manufacture and selling of human cells for cell therapy in the treatment of human diabetes and liver diseases.
License Property
The Technology is to research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, Processes and Services to produce human embryonic stem cells and to produce from those mammalian embryonic cells, differentiated cells for human cell therapy within the Field, and to produce pluripotent cells including ES cells, differentiated human cells for cell therapy within the field.

5,453,366 Method of Cloning Bovine Embryos

6,011,197 Method of Cloning Bovines Using Reprogrammed Non-mbryonic Bovine Cells

6,258,998 Method of Cloning Porcine Animals

5,843,754 Parthenogenic Bovine Oocyte Activation

5,496,720 Parthenogenic Oocyte Activation

09/573,044 Use of embryonic stem cells as nuclear donors during nuclear transfer and use of said techniques to produce chimeric and transgenic animals.

6,194,202 Parthenogenic Oocyte Activation

6,077,710  Parthenogenic Oocyte Activation

6,107,543  Culture of Totipotent Embryonic Inner Cells Mass Cells and Production of Bovine
Animals

Field of Use
The Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.

IPSCIO Record ID: 356974

License Grant
Licensor, two individuals from Italy, grants an exclusive, perpetual and irrevocable license to make, use, have made, sell, offer to sell, import, manufacture, market and distribute the Licensed Technology within the Territory. Licensee shall appoint an exclusive distributor of the Licensed Technology in Italy at the conditions to be separately agreed between the parties.
License Property
Licensor is the inventor of certain processes and devices that allow for the migration of organic cells into tissue samples while being incubated in a specialized bioreactor, the Technology.

lmprovements mean any Intellectual Property developed after the Effective Date by the Inventor/Licensor or any third party affiliated with Licensor that constitutes an improvement or enhancement of the functions of the Technology, that is associated to the Technology and that relates to a bioreactor device able to feed and repopulate a rotating tubular structure, with the exclusion of different or new functions relating to generation of electrical fields, pressure fields and fluid dynamic fields.

Field of Use
The intellectual property rights relates to our InBreath Bioreactor.

This bioreactor is the first in a series of products that Licensee is developing to address what we believe is a long-term growth opportunity in the emerging field of regenerative medicine. Regenerative medicine is a new field that uses stem cells to repair damaged organs (e.g., spinal cord and heart) and also to grow tissue (e.g., bladder and bronchus) and organs (e.g., heart and lung) outside the body for transplant.

InBreath hollow organ bioreactor is a device that can be used by a surgeon to seed cells onto a scaffold. The InBreath bioreactor enables the surgeon to
•
secure the scaffold to the bioreactor;
•
seed the patient’s cells on the scaffold under sterile conditions;
•
automatically rotate the scaffold to allow good cell distribution into the pores of the scaffold; and
•
remotely monitor the scaffold during the course of the two to three days incubation period before the transplant.
The InBreath bioreactor has several novel features such as allowing for separate cell seeding conditions on the inside and outside of the scaffold and for pumping cell culture media through the inside of the scaffold without the need for an external pump and tubes. The Licensee believe the InBreath hollow organ bioreactor is the world’s first bioreactor that has been used to perform a human transplant of a regenerated organ.

The Technology has proven beneficial medical uses in organ transplant as well as the potential for use in other areas.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.